Skip to content
Studies have shown that active fund managers routinely underperform the S&P500 index*
Home
Articles
WALL STREET X
Forecasts
Portfolios
Wall Street X
Articles
Forecasts
Portfolios
Search
Results for
{phrase}
(
{results_count}
of
{results_count_total}
)
Displaying
{results_count}
results of
{results_count_total}
Cytek Biosciences, Inc. (NASDAQ: CTKB)
CTKB Stock Predictions and Ratings
WSX Rating:
HOLD
WSX Forecast (1yr):
2.90%
Analyst Rating:
BUY
Analyst Forecast (1yr):
62.80%
CTKB Stock Analysis
CTKB
PE Ratio:
CTKB
PEG Ratio:
Not Available
CTKB
Forward EPS Growth (12 month):
0.00%
CTKB
PS Ratio:
2.6
CTKB
PSG Ratio:
0.4
CTKB
Forward Revenue Growth (12 month):
6.60%
CTKB Articles
No data was found